Summary & Overview
HCPCS Level II C9488: Injection, Conivaptan Hydrochloride, 1 mg
HCPCS Level II code C9488 denotes a 1 mg unit of conivaptan hydrochloride for injection, an IV medication used in hospital settings for management of conditions requiring vasopressin receptor antagonism. Nationally, this code matters for hospital drug billing, inpatient and outpatient medication inventories, and payer coverage determinations for high-cost injectable therapies. Payers commonly involved in coverage and reimbursement decisions include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare.
Readers will find benchmarks and operational context for billing and coding this medication unit, an overview of payer coverage patterns, and clinical context explaining typical settings and use. The publication summarizes common modifiers and service-line considerations, highlights documentation elements relevant to billing, and outlines where data is unavailable. This coverage is intended to inform revenue cycle, pharmacy billing, and clinical administrators about how C9488 is represented in claims and the key administrative factors that affect processing and reimbursement nationally.
Billing Code Overview
HCPCS Level II code C9488 represents an injectable medication: injection, conivaptan hydrochloride, 1 mg. This code describes a single unit of the drug formulation used for parenteral administration.
-
Service type: Intravenous medication administration (IV infusion or injection)
-
Typical site of service: Hospital inpatient or outpatient settings, including acute care units, observation units, and emergency departments where intravenous vasopressor/antidiuretic management is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult hospitalized with euvolemic or hypervolemic hyponatremia refractory to fluid restriction and requiring pharmacologic therapy. The patient often presents with serum sodium <125 mEq/L or symptomatic hyponatremia (confusion, nausea, headache, seizures) where rapid correction must be avoided. Conivaptan hydrochloride is administered intravenously as a continuous infusion following an initial loading dose; the drug is used to antagonize vasopressin V1A/V2 receptors to promote aquaresis.
The clinical workflow includes: initial assessment in the emergency department or inpatient ward, baseline labs (serum sodium, osmolality, renal and hepatic panels), confirmation of euvolemic or hypervolemic status, insertion of a peripheral or central IV line, administration of a loading dose followed by continuous infusion per protocol, frequent monitoring of serum sodium (every 4–6 hours during active correction), fluid balance monitoring, adjustment or discontinuation of infusion based on response, and documentation of indication, doses, start/stop times, and observed adverse events. Typical sites of service are inpatient hospital units, intensive care units, and emergency departments where IV infusions and close monitoring occur.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; full coverage | Use when no specific modifier applies and billing as standard drug administration occurs |